Piotr Wysocki: Striking activity of metronomic chemotherapy in a critically advanced cutaneous squamous cell cancer
Piotr Wysocki recently shared on LinkedIn:
“In many countries, the availability of checkpoint inhibitors-based immunotherapy is limited or even does not exist. Especially in the case of rare tumors such as cutaneous squamous cell cancer (SCC), for many patients around the world, novel, active drugs are entirely unavailable.
Here we present a case of a patient with critically advanced skin SCC who achieved a complete, long-term response to a skilfully optimized metronomic chemotherapy. This case confirms that a good understanding of disease properties and biological features allows for an optimal combination of cheap, cytotoxic drugs, which may lead to a profound clinical benefit.”
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023